fda semaglutide ban Fifth Circuit probes on compounded GLP-1s FDA ends semaglutide shortage, closing

Treatment Options at WeightWatchers WeightWatchers clinicians may prescribe FDA-approved, brand-name GLP-1 medications, focusing on safety and proven results

Additionally, by reducing weight, many users experience improvements in other obesity-related conditions, such as sleep apnea, hypertension, and high cholesterol levels

Am J Gastroenterol 92: 2069-2072, 1997

Low-dose naltrexone as a modulator of microglial activation: potential neuroprotective implications

GLP-1 medicines may increase the risk of gallbladder problems, including gallstones and gallbladder inflammation

Research indicates that gastroparesis may be more common in patients who take GLP-1 drugs like Ozempic than in people who take other weight loss drugs